Heron Therapeutics (HRTX) News Today $1.85 -0.02 (-1.07%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.83 -0.02 (-1.08%) As of 05/23/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Heron Therapeutics (NASDAQ:HRTX) Stock Rating Lowered by Wall Street ZenWall Street Zen lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday.May 24 at 11:22 AM | marketbeat.comPoint72 Asset Management L.P. Purchases Shares of 3,075,809 Heron Therapeutics, Inc. (NASDAQ:HRTX)Point72 Asset Management L.P. purchased a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,075,809 shares of the biotechnology coMay 22 at 4:42 AM | marketbeat.comStonepine Capital Management LLC Invests $1.07 Million in Heron Therapeutics, Inc. (NASDAQ:HRTX)Stonepine Capital Management LLC bought a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 700,000 shares of the biotechnology company's stockMay 20, 2025 | marketbeat.comTang Capital Management LLC Boosts Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)Tang Capital Management LLC boosted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 15.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,140,271 shares of the biotechnologMay 20, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 660,971 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)D. E. Shaw & Co. Inc. lowered its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 15.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,723,706 shares of the biotechnoloMay 19, 2025 | marketbeat.comRaymond James Financial Inc. Buys Shares of 135,722 Heron Therapeutics, Inc. (NASDAQ:HRTX)Raymond James Financial Inc. purchased a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 135,722 shares of the biotechnology company's stMay 15, 2025 | marketbeat.comJ. Goldman & Co LP Acquires Shares of 270,100 Heron Therapeutics, Inc. (NASDAQ:HRTX)J. Goldman & Co LP bought a new position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 270,100 shares of the biotechnology company's stock, valued at apprMay 14, 2025 | marketbeat.com300,000 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Bought by Bridgeway Capital Management LLCBridgeway Capital Management LLC purchased a new position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 300,000 shares of theMay 14, 2025 | marketbeat.comQ2 Earnings Estimate for HRTX Issued By Northland CapmkHeron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Stock analysts at Northland Capmk issued their Q2 2025 earnings estimates for shares of Heron Therapeutics in a research note issued on Tuesday, May 6th. Northland Capmk analyst C. Byrnes expects that the biotechnology company will post earniMay 10, 2025 | marketbeat.comClearline Capital LP Cuts Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)Clearline Capital LP trimmed its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 18.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,810,483 shares of the biotechnology company'sMay 10, 2025 | marketbeat.comResults: Heron Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 9, 2025 | finance.yahoo.comHeron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Beats Expectations By $0.03 EPSHeron Therapeutics (NASDAQ:HRTX - Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03.May 8, 2025 | marketbeat.comHeron Therapeutics Target of Unusually High Options Trading (NASDAQ:HRTX)Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) saw some unusual options trading on Tuesday. Stock traders purchased 11,901 call options on the stock. This is an increase of approximately 1,867% compared to the typical volume of 605 call options.May 8, 2025 | marketbeat.comEarnings call transcript: Heron Therapeutics beats Q1 2025 expectations, stock surgesMay 7, 2025 | investing.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Call TranscriptMay 7, 2025 | insidermonkey.comHeron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ...May 7, 2025 | finance.yahoo.comHeron Therapeutics, Inc.: Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate UpdatesMay 6, 2025 | finanznachrichten.deHeron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comHeron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate UpdatesMay 6, 2025 | prnewswire.comHeron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent LitigationsMay 6, 2025 | prnewswire.comHeron Therapeutics (HRTX) Projected to Post Quarterly Earnings on TuesdayHeron Therapeutics (NASDAQ:HRTX) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-heron-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comMarshall Wace LLP Lowers Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)Marshall Wace LLP lessened its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 40.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,017,539 shares of the biotechnology company's stock after selling 698,006 shares duMay 1, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. cut its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 8,500,000 shares of the biotechnology company's stock after selling 350April 30, 2025 | marketbeat.comHeron Therapeutics, Inc.: Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating OfficerApril 30, 2025 | finanznachrichten.deHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by JPMorgan Chase & Co.JPMorgan Chase & Co. grew its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 172.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 562,764 shares of the biotechnology company's stock after purchasing an additionApril 30, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC lessened its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 40.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,188,800 shares of the biotechnology company's stock after sellingApril 29, 2025 | marketbeat.comHeron Therapeutics Announces Appointment of Mark Hensley as Chief Operating OfficerApril 28, 2025 | prnewswire.comHeron Therapeutics (NASDAQ:HRTX) Stock Price Passes Above 200-Day Moving Average - Should You Sell?Heron Therapeutics (NASDAQ:HRTX) Share Price Passes Above 200 Day Moving Average - Here's WhyApril 25, 2025 | marketbeat.comHeron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025April 22, 2025 | prnewswire.comQuinn Opportunity Partners LLC Takes Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)Quinn Opportunity Partners LLC bought a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 380,000 shares of the biotechnology company's stockApril 14, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)Raymond James Financial Inc. purchased a new position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 135,722 shares of the biotechnology company'sApril 14, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a report on Friday.April 13, 2025 | marketbeat.comLoss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected To Breakeven In The Medium-TermMarch 29, 2025 | finance.yahoo.comIs Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5?March 26, 2025 | insidermonkey.comRichmond Brothers Inc. Has $983,000 Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)Richmond Brothers Inc. increased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 25.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 642,339 sharesMarch 20, 2025 | marketbeat.comTejara Capital Ltd Has $7.13 Million Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)Tejara Capital Ltd reduced its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 12.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,661,547 shares of the biotechnology company's stock after sellinMarch 19, 2025 | marketbeat.comMonaco Asset Management SAM Sells 465,674 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)Monaco Asset Management SAM decreased its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 27.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,212,743 shares of the biotechnology company's stock after selling 465,674 shares duringMarch 15, 2025 | marketbeat.comCM Management LLC Has $1.07 Million Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)CM Management LLC raised its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 40.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 700,000 shares of the biotechnology company's stock after purchasing an additional 200,000 sharesMarch 9, 2025 | marketbeat.comHeron Therapeutics (HRTX) to Release Quarterly Earnings on TuesdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666518)March 9, 2025 | marketbeat.comHeron Therapeutics: Four Horse Race Of Approved TherapiesMarch 8, 2025 | seekingalpha.comHeron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to HoldStockNews.com lowered Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday.March 8, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Stock Position Decreased by Los Angeles Capital Management LLCLos Angeles Capital Management LLC decreased its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 69.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 67,653 shares of the biotechnology company'sMarch 6, 2025 | marketbeat.comHeron Therapeutics (HRTX) to Release Earnings on TuesdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666518)March 4, 2025 | marketbeat.comBrokers Offer Predictions for HRTX Q1 EarningsHeron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Investment analysts at Northland Capmk issued their Q1 2025 EPS estimates for Heron Therapeutics in a research note issued to investors on Thursday, February 27th. Northland Capmk analyst C. Byrnes forecasts that the biotechnology company wilMarch 3, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported Earnings, And Analysts Cut Their Target PriceMarch 2, 2025 | finance.yahoo.comHeron Therapeutics (NASDAQ:HRTX) Upgraded to Buy at StockNews.comStockNews.com upgraded shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday.March 1, 2025 | marketbeat.comHeron Therapeutics' (HRTX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Friday.March 1, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Expectations By $0.05 EPSHeron Therapeutics (NASDAQ:HRTX - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05.February 28, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPSHeron Therapeutics (NASDAQ:HRTX - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.05.February 28, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) shareholders are up 19% this past week, but still in the red over the last five yearsFebruary 28, 2025 | uk.finance.yahoo.com Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTX Media Mentions By Week HRTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HRTX News Sentiment▼1.420.75▲Average Medical News Sentiment HRTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HRTX Articles This Week▼52▲HRTX Articles Average Week Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 89bio News Today Aurinia Pharmaceuticals News Today Gyre Therapeutics News Today Mineralys Therapeutics News Today Wave Life Sciences News Today Phibro Animal Health News Today Ardelyx News Today Collegium Pharmaceutical News Today Intellia Therapeutics News Today Arcus Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HRTX) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HRTX Stock Free HRTX Stock Alerts